ENOV

NYSE Enovis Corporation

Nov 4, 2026 · 8:31 AM ET LAST TRADE Market Closed

$0.0000 ↓ -20.8900 (-100.00%) Trading Down from the previous close of $20.8900

YTD change: N/A
vs 20-day SMA: N/A
vs 200-day SMA: N/A

Price ranges

Previous day

$20.34 $21.53

open $20.63 close $20.89

+$0.26 (+1.26%)

Today

$0.0000 $0.0000

$0.0000

Past week

$19.8300 $22.8400

from $21.5400 now $0.0000

-$21.5400 (-100.00%)

Past month

$16.7000 $22.8400

from $18.2000 now $0.0000

-$18.2000 (-100.00%)

This year

$16.7000 $31.6650

from $26.6400 now $0.0000

-$26.6400 (-100.00%)

Price & Performance

-2.45 (-10.50%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor

The stock is 100.0% away from all-time highs of $72.1300
ENOV is down 100% since the beginning of the year
ENOV is down 100% over the past 12 months
ENOV is down 100% over the past 1 month
21% of all ENOV investors are betting against ENOV
Number of investors short ENOV has gone up 11% versus last month

ENOV reads poor: short interest is rising month over month, the 12-month move is -33.6%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes

EPS $0.9

Earnings momentum -17.3% Quarterly EPS growth

Quarterly change -17.3%

Valuation

P/E ratio N/A

Enterprise value $2.6B

Beta 0.92

Balance sheet & scale

IncomeN/A

Revenue$2.3B

Cash$12.6M

Debt$1.4M

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNYSE

Sector Manufacturing

Sub Sector Miscellaneous Manufacturing

Market cap N/A

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Competitor comparison

Ticker	Company	Price	Change
JNJ.CAT	JOHNSON & JOHNSON CDR CAD HEDGED	$33.86	-1.83%
BDX	Becton, Dickinson and Company	$198.17	-0.22%
DXCM	DexCom, Inc.	$82.97	-2.11%
MDLN	Medline, Inc. Class A	$34.09	+1.37%
WST	West Pharmaceutical Services, Inc.	$406.99	-0.22%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.